Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
Rhea-AI Summary
Illumina has unveiled its MiSeq i100 Series of sequencing systems, designed to make next-generation sequencing (NGS) more accessible. The new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, offer unparalleled speed and simplicity for labs.
Key features include:
- Room-temperature reagent storage and shipping
- 85% reduction in packaging waste
- Run times as fast as four hours
- Cost-effective consumables
- 18 proven end-to-end workflows across 10 applications
- Simplified operations for various experience levels
The MiSeq i100 Series builds on the legacy of the original MiSeq System, incorporating technology from the NovaSeq X Series. It offers flexible output capabilities, with the MiSeq i100 Plus System providing 100 million single-end reads per run, and the MiSeq i100 System offering 25 million.
Early access testing has received positive feedback from customers, highlighting the instrument's speed, flexibility, and ease of use. The MiSeq i100 will be available globally in 2025.
Positive
- Introduction of new MiSeq i100 Series with improved speed and simplicity
- Room-temperature reagent storage and shipping, enabling on-demand sequencing
- 85% reduction in packaging waste, supporting sustainability efforts
- Faster run times (as quick as 4 hours) compared to previous models
- Cost-effective consumables for more affordable sequencing
- 18 proven end-to-end workflows across 10 applications
- Simplified operations suitable for various levels of sequencing experience
Negative
- None.
Insights
The introduction of the MiSeq i100 Series represents a significant advancement in benchtop sequencing technology. Key innovations include:
- Room-temperature reagent storage and shipping, eliminating the need for cold chain logistics
- Faster run times (up to 4x faster than previous MiSeq systems)
- Simplified workflows suitable for users with varying levels of NGS expertise
- Cost-effective consumables for more affordable sequencing
- Reduced environmental impact with 85% less packaging waste
These improvements address critical pain points in the NGS market, potentially expanding Illumina's customer base to include smaller labs and those new to sequencing. The system's flexibility and ease of use could drive increased adoption of NGS technology across various applications, from microbiology to oncology.
For investors, this product launch signals Illumina's continued innovation and market leadership in the sequencing space. The MiSeq i100 Series could help Illumina maintain its competitive edge and potentially capture new market segments, particularly in settings where speed, simplicity and cost-effectiveness are crucial.
The launch of the MiSeq i100 Series is strategically significant for Illumina and the broader NGS market. This product addresses several key market trends:
- Democratization of sequencing: By simplifying workflows and reducing costs, Illumina is making NGS more accessible to a wider range of labs.
- Demand for faster results: The rapid turnaround time (as fast as 4 hours) caters to time-sensitive applications in clinical and research settings.
- Sustainability focus: The reduced packaging waste and elimination of cold chain requirements align with growing environmental concerns in the scientific community.
The MiSeq i100 Series could potentially expand Illumina's total addressable market by attracting new customers who previously found NGS too complex or expensive. This move also helps Illumina defend its market position against emerging competitors in the benchtop sequencing space.
While the full financial impact won't be clear until after the 2025 launch, this product line has the potential to drive significant revenue growth for Illumina, especially if it can capture market share in emerging applications like infectious disease surveillance and targeted oncology panels.
Designed to make next-generation sequencing accessible to more labs
With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries
The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, will empower customers to unlock powerful insights through an affordable, comprehensive solution that is simple to understand and use, even for those with limited NGS expertise. Room-temperature storage and shipping enable labs to sequence on demand, with no delays for thaw time, and same-day sample-to-analysis.
"Our customers told us they need a faster, smaller, and easy-to-use instrument, and that's what we're delivering with the MiSeq i100," said Jacob Thaysen, PhD, CEO of Illumina. "Whether you are an established next-generation sequencing lab, or looking to start sequencing for the first time, our latest benchtop instrument adds the plug-and-play flexibility that today's labs are seeking."
The MiSeq i100 Series builds on the legacy of the original benchtop MiSeq System, which Illumina customers have used since 2011 to power a host of genomic discoveries. Completely redesigned and incorporating the groundbreaking technology and chemistry of the NovaSeq™ X Series, the MiSeq i100 will help to fuel the next era of genomics growth and discovery.
Key technology enhancements
The MiSeq i100 Series brings Illumina's powerful XLEAP-SBS™ chemistry innovation even further—for the first time, harnessing the potential of room-temperature storage and shipping, which provides customers greater flexibility in how they plan and execute their projects while reducing their environmental impact. It offers flexible output capabilities and comes in two configurations: the MiSeq i100 Plus System has the full 100 million single-end reads per run, and the MiSeq i100 System has a maximum of 25 million single-end reads per run. Key features include:
- Room-temperature shipping and storage for reagents: Eliminating the cold chain and allowing for greater flexibility to sequence on demand without the need to thaw reagents, which is critical for running urgent samples
- Sustainability: An
85% reduction in packaging waste compared to the MiSeq System supports a lower carbon footprint - Speed: Dramatic reduction in run times: as fast as four hours, with same-day results (4× faster than MiSeq)
- Cost efficiency: Cost-effective consumables enable more affordable sequencing
- Turnkey workflows: 18 proven end-to-end workflows across 10 applications
- Simplicity: Simpler, streamlined operations for various levels of sequencing experience
Push-button workflows on MiSeq i100 are available for small whole-genome sequencing for microbiology and targeted NGS panels for both infectious disease and oncology. Workflows provide metrics either directly on the instrument or via cloud-based DRAGEN™ genomic data analysis, minimizing the need for bioinformatics expertise.
"The MiSeq i100 symbolizes Illumina's commitment to delivering total systems with complete workflows that allow our customers to accomplish more," said Steve Barnard, PhD, chief technology officer of Illumina. "With its enhanced speed, simplicity, scalability, and quality–and its intuitive user experience–the MiSeq i100 sets a new standard for benchtop sequencing."
Customer reactions
Illumina conducted early access testing of MiSeq i100 with customers around the world. Geneviève DonPierre, team leader of NGS Sequencing at Génome
Génome Québec is a nonprofit organization that provides genomic services for researchers in the academic and industrial fields of 45 countries. DonPierre noted the importance of room temperature storage for her lab: "It really helps the planning for the sequencing run. We don't have to think two days before to get a kit out of the freezer. So it really is a game changer to have kits stored at room temperature."
Tim Roloff Handschin, PhD, co-leader of Microbial Genomics (NGS) at the Institute for Medical Microbiology at the University of
"We can start two runs on the same day and thereby increase our sample flow massively. And given that the reagents are shipped at room temperature, we don't need to wait for the cartridges to thaw," Roloff said. "We can just launch a run whenever we're ready with a new pool and there is no planning needed upfront. This gives us great flexibility, and this can provide new possibilities to develop new tests."
The new instrument was unveiled during a virtual customer event; a replay may be viewed here. The MiSeq i100 will be available to ship globally in 2025. For more information, visit the website.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) our ability to manufacture robust instrumentation and consumables; (iii) customer uptake of, and satisfaction with new products and services; and (iv) the speed and scale of new product adoption by customers, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-introduces-the-miseq-i100-series-its-simplest-fastest-benchtop-sequencers-302270917.html
SOURCE Illumina, Inc.
FAQ
When will the Illumina MiSeq i100 Series be available for purchase (ILMN)?
What are the key features of the new Illumina MiSeq i100 Series (ILMN)?
How does the MiSeq i100 Series differ from the original MiSeq System (ILMN)?
What are the output capabilities of the MiSeq i100 and MiSeq i100 Plus Systems (ILMN)?
